Renaissance Technologies LLC Has $82,000 Holdings in BioAtla, Inc. $BCAB

Renaissance Technologies LLC trimmed its position in BioAtla, Inc. (NASDAQ:BCAB) by 27.8% in the first quarter, Holdings Channel reports. The fund owned 510,514 shares of the company’s stock after selling 196,700 shares during the quarter. Renaissance Technologies LLC owned 0.31% of BioAtla worth $82,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of BCAB. Woodline Partners LP bought a new stake in BioAtla during the 1st quarter worth $26,000. Jane Street Group LLC raised its position in BioAtla by 55.4% in the fourth quarter. Jane Street Group LLC now owns 346,774 shares of the company’s stock valued at $197,000 after purchasing an additional 123,597 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of BioAtla by 9.1% during the third quarter. Vanguard Group Inc. now owns 1,945,795 shares of the company’s stock valued at $1,339,000 after purchasing an additional 162,647 shares in the last quarter. Susquehanna International Group LLP boosted its stake in shares of BioAtla by 237.6% during the third quarter. Susquehanna International Group LLP now owns 252,583 shares of the company’s stock valued at $174,000 after purchasing an additional 177,760 shares in the last quarter. Finally, ADAR1 Capital Management LLC bought a new stake in shares of BioAtla during the fourth quarter worth about $104,000. Institutional investors and hedge funds own 77.23% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of BioAtla in a research note on Wednesday, June 3rd. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $200.00.

BioAtla Stock Performance

BCAB stock opened at $3.18 on Friday. The company has a fifty day moving average price of $3.62 and a 200-day moving average price of $5.43. The company has a market capitalization of $5.28 million, a P/E ratio of -0.12 and a beta of 0.78. BioAtla, Inc. has a 52-week low of $2.81 and a 52-week high of $71.50.

BioAtla (NASDAQ:BCAB) last issued its quarterly earnings data on Thursday, August 13th. The company reported $0.14 earnings per share for the quarter, topping the consensus estimate of ($8.50) by $8.64. The business had revenue of $6.50 million during the quarter, compared to the consensus estimate of $6.50 million.

BioAtla Company Profile

BioAtla, Inc (NASDAQ: BCAB) is a clinical‐stage biotechnology company focused on the development of conditionally active biologics (CABs) for oncology and other serious diseases. Utilizing its proprietary CAB technology platform, BioAtla engineers monoclonal antibodies, bispecifics and antibody-drug conjugates that remain inactive in healthy tissues but become activated in the tumor microenvironment. This targeted approach aims to improve therapeutic index by enhancing anti‐tumor potency while minimizing off-target effects and systemic toxicity.

Founded in 2012 and headquartered in San Diego, California, BioAtla has advanced multiple product candidates into clinical trials.